Biofilm · 2026
Enhanced activity of octiset® versus octenidine against polymicrobial bacterial vaginosis biofilms in vitro and ex vivo.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Castro Filipa O, Mulinde Taynara, Sousa Lúcia G V, Bartling Pascal, Zwingenberger Gwen, Cerca Nuno
Аннотация
BACKGROUND: Bacterial vaginosis (BV) is the most common vaginal infection in women of reproductive age and is strongly associated with polymicrobial biofilms, which contribute to antimicrobial tolerance and high recurrence rates. New strategies targeting BV-associated biofilms are therefore needed. This study evaluated the antimicrobial and antibiofilm activity of octenidine dihydrochloride/phenoxyethanol (Octiset®) compared with octenidine dihydrochloride (octenidine) alone in in vitro and ex vivo BV biofilm models.
METHODS: Planktonic cultures and biofilms of BV-associated species (Gardnerella vaginalis, Fannyhessea vaginae, Prevotella bivia, Peptostreptococcus anaerobius and Mobiluncus curtisii) were established under anaerobic conditions. Planktonic suspensions were exposed for 24 h to octiset® (50%, 25%) or octenidine (0.1%, 0.05%). Single-species and polymicrobial biofilms were formed for 24 h and treated with octiset® or octenidine up to 12 h. Additionally, polymicrobial biofilms were established on reconstructed human vaginal epithelium (SkinEthic™ HVE) and treated for 8 h. Antimicrobial efficacy was assessed by CFU quantification. Recovery experiments were performed to determine whether residual culturable cells persisted after treatment, by incubating samples in fresh medium for up to 72 h and subsequently quantifying CFUs. Antimicrobial activity was also tested against species associated with healthy vaginal microbiota, by assessing vaginal lactobacilli susceptibility to both compounds.
RESULTS: Both compounds showed time- and concentration-dependent activity. Octiset® consistently demonstrated superior killing compared to octenidine, including eradication of several single-species biofilms. Polymicrobial biofilms showed increased tolerance; however, extended exposure (≥8 h) reduced CFUs below detection for both agents, with no regrowth observed after 72 h. In the ex vivo model, both treatments reduced biofilm growth below the limit of detection. All tested lactobacilli also showed susceptibility to both compounds.
CONCLUSION: Octiset® and octenidine exhibited strong antibiofilm activity against BV-associated polymicrobial biofilms in vitro and ex vivo, supporting their potential as biofilm-targeted BV treatment approaches.
METHODS: Planktonic cultures and biofilms of BV-associated species (Gardnerella vaginalis, Fannyhessea vaginae, Prevotella bivia, Peptostreptococcus anaerobius and Mobiluncus curtisii) were established under anaerobic conditions. Planktonic suspensions were exposed for 24 h to octiset® (50%, 25%) or octenidine (0.1%, 0.05%). Single-species and polymicrobial biofilms were formed for 24 h and treated with octiset® or octenidine up to 12 h. Additionally, polymicrobial biofilms were established on reconstructed human vaginal epithelium (SkinEthic™ HVE) and treated for 8 h. Antimicrobial efficacy was assessed by CFU quantification. Recovery experiments were performed to determine whether residual culturable cells persisted after treatment, by incubating samples in fresh medium for up to 72 h and subsequently quantifying CFUs. Antimicrobial activity was also tested against species associated with healthy vaginal microbiota, by assessing vaginal lactobacilli susceptibility to both compounds.
RESULTS: Both compounds showed time- and concentration-dependent activity. Octiset® consistently demonstrated superior killing compared to octenidine, including eradication of several single-species biofilms. Polymicrobial biofilms showed increased tolerance; however, extended exposure (≥8 h) reduced CFUs below detection for both agents, with no regrowth observed after 72 h. In the ex vivo model, both treatments reduced biofilm growth below the limit of detection. All tested lactobacilli also showed susceptibility to both compounds.
CONCLUSION: Octiset® and octenidine exhibited strong antibiofilm activity against BV-associated polymicrobial biofilms in vitro and ex vivo, supporting their potential as biofilm-targeted BV treatment approaches.